Committee approves referral for bill to boost transparency of health‑care ownership and bar corporate interference in clinical decisions

Sen. Mann presented Senate File 2939 on March 10, 2026, a two‑part bill intended to increase transparency about healthcare ownership and financing and to add statutory protections against corporate interference in clinical decisions (the "corporate practice of medicine" provisions).

Yashaswini Singh, a health‑care economist and assistant professor at Brown University, testified about the growth of private equity investment in healthcare nationally and the limits of current disclosure. She said PE investments have shifted toward outpatient settings and often rely on high leverage and short time horizons, and summarized research associating PE ownership with higher costs and mixed quality effects in several settings. Singh and other testifiers highlighted the difficulty policymakers face because ownership chains and debt arrangements are often opaque.

Stu Lourey, Government Relations Director for the Minnesota Farmers Union, and Dr. Bruce Bostrom, a retired pediatric oncologist, testified in support, describing consolidation and private‑equity pressure as factors increasing cost and harming local access in rural communities. Committee members raised concerns about administrative burden for providers. Sen. Koran and others questioned whether reporting requirements in the bill would be onerous to organizations and whether the transparency requirements were proportional to the goal.

After discussion, Sen. Mann moved that SF 2939, as amended, be recommended to pass and referred to the Committee on State and Local Government. The motion carried by voice vote as recorded in the hearing. Committee members signaled support for additional transparency even as they sought to limit burdens on frontline providers.

Next steps: SF 2939 was referred to State and Local Government for further consideration; committee staff will prepare the record for that referral.